Phuturdex › Diseases › Multibacillary leprosy
Drugs in development · updated 9 November 2026
Multibacillary leprosy: drugs in development
What it is
A form of LEPROSY classified by the World Health Organization for the purpose of treatment, based on clinical manifestations and skin smear results. Patients with multibacillary leprosy have six or more lesions with or without positive skin smear results for the causative agent MYCOBACTERIUM LEPRAE. Multibacillary leprosy encompasses borderline lepromatous, midborderline, and lepromatous leprosy.
Source: NLM MeSH (U.S. National Library of Medicine), descriptor D056006, meshb.nlm.nih.gov · public domain · downloaded on 9 November 2026.
As of 9 November 2026 there are 2 active clinical trials (recruiting or ongoing, phases I–III) on 3 drugs for multibacillary leprosy. One is experimental, that is not yet approved in the United States.
Summary updated every week · data as of 9 November 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Telacebec | II | 1 | NCT07918573 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| MetforminMetfomin, Riomet Er® | II | 1 | NCT05243654 |
| RifampicinRifampin, RIFADIN | II | 1 | NCT07918573 |
Sorted by most advanced phase and number of active trials.
All 3 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Infection 876 drugs
- Mycobacterium Infections 77 drugs
- Mycobacterium Infections, Nontuberculous 29 drugs
- Bacterial Infections 204 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 9 November 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D056006 “Leprosy, Multibacillary”.